Liver Volumetry and Treatment Response in Uveal Melanoma
Author Information
Author(s): Sebastian Zensen, Hannah L Steinberg-Vorhoff, Aleksandar Milosevic, Heike Richly, Jens T Siveke, Marcel Opitz, Johannes Haubold, Yan Li, Michael Forsting, Benedikt Michael Schaarschmidt
Primary Institution: University Hospital Essen, Germany
Hypothesis
Can liver volumetry improve the evaluation of treatment response to hepatic artery infusion chemotherapy in uveal melanoma patients with liver metastases?
Conclusion
Liver volumetry with a 10% increase threshold is effective for evaluating treatment response in uveal melanoma patients with liver metastases.
Supporting Evidence
- Liver volumetry identified patients with significantly reduced overall survival.
- A 10% increase in liver volume was the threshold for classifying patients as having progressive disease.
- Median overall survival was 15.9 months for stable disease and 6.6 months for progressive disease.
Takeaway
This study shows that measuring liver size can help doctors see if treatment is working for patients with eye cancer that has spread to the liver.
Methodology
The study evaluated treatment response in 143 uveal melanoma patients using liver volumetry and RECIST 1.1 criteria on CT scans before and after hepatic artery infusion chemotherapy.
Potential Biases
Evaluation by the same radiologist for all examinations may introduce bias.
Limitations
The study is retrospective and conducted at a single center, which may limit the generalizability of the findings.
Participant Demographics
Mean age 65.1 years, 54% female.
Statistical Information
P-Value
<0.001
Confidence Interval
95% CI 11.2–15.8 months
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website